clinical trial · NCT07023627
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian CancerINCB123667
brief summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
started
Nov 12, 2025
primary completion
Apr 27, 2027
completion
Oct 24, 2027
last updated
Aug 6, 2026
official title
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol